KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Debt to Equity (2016 - 2025)

Inovio Pharmaceuticals' Debt to Equity history spans 16 years, with the latest figure at -$6.53 for Q3 2025.

  • For Q3 2025, Debt to Equity changed N/A year-over-year to -$6.53; the TTM value through Sep 2025 reached -$6.53, changed N/A, while the annual FY2024 figure was $0.19, 35.39% up from the prior year.
  • Debt to Equity for Q3 2025 was -$6.53 at Inovio Pharmaceuticals, down from $0.4 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.4 in Q2 2025 and bottomed at -$6.53 in Q3 2025.
  • The 5-year median for Debt to Equity is $0.01 (2022), against an average of -$0.36.
  • The largest annual shift saw Debt to Equity plummeted 55.82% in 2021 before it soared 2093.56% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $0.0 in 2021, then surged by 346.76% to $0.01 in 2022, then skyrocketed by 2232.88% to $0.14 in 2023, then skyrocketed by 35.39% to $0.19 in 2024, then tumbled by 3472.92% to -$6.53 in 2025.
  • Per Business Quant, the three most recent readings for INO's Debt to Equity are -$6.53 (Q3 2025), $0.4 (Q2 2025), and $0.19 (Q1 2025).